2024年10月,亿腾医药通过反向收购嘉和生物实现港股上市。其长达四年的IPO挫折后选择“借壳”突围,估值达6.77亿美元。然而,公司2024年销售及分销开支飙升至7.31亿元,会议开支达2.23亿元,远超同期研发费用1.22亿元,引发对“重销售轻研发”模式的质疑。此外,上市前半年内突击分红1.44亿元,实控人独得6300万元,被指“掏空式分红”。未来,亿腾嘉和寄希望于创新药管线纳入医保以推动增长...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.